長期的に無症候性の病気からイマチニブを中止した慢性期慢性骨髄性白血病患者におけるチロシンキナーゼ阻害療法再開のトリガーとしての主要分子反応の喪失

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study2013 · 706 citations
2. 2Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories2007 · 107 citations
3. 3Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa2002 · 117 citations
4. 4Follow-Up of Complete Cytogenetic Remission in Patients With Chronic Myeloid Leukemia After Cessation of Interferon Alfa2002 · 73 citations
5. 5Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplantation for chronic myeloid leukemia: an attempt to define patients who may not require further therapy2006 · 126 citations